Sean Parker’s immuno-oncology institute has allied with Tessa Therapeutics to turn T-cell therapies against solid tumors. The agreement brings virus-specific T cell specialist Tessa into the network Parker and his collaborators created to foster cancer immunotherapy collaborations.
Singapore-based Tessa has built its R&D operation on IP licensed from Baylor College of Medicine and taken its lead drug as far as a phase 3 trial. That study is investigating the efficacy of Tessa’s adoptive T-cell therapy as a monotherapy in nasopharyngeal cancer patients who have undergone treatment with the chemotherapies gemcitabine and carboplatin. But Tessa sees the combination of its T-cell therapies and other immuno-oncology drugs furthering its pipeline prospects.